So many cardiometabolic conditions are interconnected, such as obesity, diabetes, and cardiovascular disease. This is making us take a broader look into patient challenges and how we curate therapies that address their needs.

Our research continues to focus on advancing therapies that can address multiple cardiometabolic conditions, with an emphasis on improving accessibility for patients.

Clinical trial results are essential in our research and are at the foundation of everything we do to ensure we deliver for patients. They help us understand what works, guide our next steps, and show real progress. That’s what is most exciting about sharing our work—it’s our opportunity to show healthcare professionals and patients what we are doing to drive progress.

We know we can’t do our research alone, and we recognize that innovation takes form beyond just a medicine or a type of therapy. Our relationships and collaborations are central to our mission.

One of the things that is so unique about Novo Nordisk is how we expand health awareness through our partnerships in the community. For example, we were a founding sponsor of the Know Diabetes By Heart™ initiative, a program run by a collaboration between the American Heart Association and American Diabetes Association.

Knowing cardiovascular disease is a leading cause of death for adults living with type 2 diabetes,^2,3 our mission at Novo Nordisk is to combat the national public health impact of these conditions. We understand the link between type 2 diabetes and cardiovascular disease, and we strive to support both patients and healthcare professionals with the latest clinical guidelines and to work with health systems to improve quality of care.

We are dedicated to driving change across the full spectrum of cardiometabolic health. Looking ahead, I’m hopeful for a future where we can provide people with more therapeutic options that have the potential to help them live longer, healthier lives.